Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 570 for:    Genetic AND SNP

Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00436696
Recruitment Status : Completed
First Posted : February 19, 2007
Last Update Posted : August 7, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:
This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.

Condition or disease Intervention/treatment
Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Recurrent Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Other: Laboratory Biomarker Analysis

Detailed Description:

OBJECTIVES:

I. Perform a whole genome scan for association of neuroblastoma with single nucleotide polymorphisms (SNP) and SNP haplotypes.

II. Identify true disease-associated SNP alleles using a customized genotyping platform enriched for haplotype analyses in an independent sample set.

III. Validate disease-associated SNP alleles and haplotypes in a final independent sample set.

IV. Identify neuroblastoma predisposition genes.

OUTLINE: This is a multicenter study. Participants are stratified according to presence of high-risk disease (yes vs no) and MYCN amplification (yes vs no).

DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.

Patients do not receive the results of the genetic testing. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the Children's Oncology Group.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 9350 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Genetic Basis of Neuroblastoma Tumorigenesis
Actual Study Start Date : December 11, 2006
Actual Primary Completion Date : May 5, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Group/Cohort Intervention/treatment
Ancillary-correlative (SNP analysis)
DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
Other: Laboratory Biomarker Analysis
Correlative studies




Primary Outcome Measures :
  1. Neuroblastoma predisposition genes [ Time Frame: Up to 4 years ]
  2. Single nucleotide polymorphism (SNP) allele disease association [ Time Frame: Up to 4 years ]
  3. SNP haplotype disease association [ Time Frame: Up to 4 years ]
  4. Validation of SNP allele and haplotype disease association [ Time Frame: Up to 4 years ]
  5. SNP association with phenotypic subsets (i.e., high-risk vs no high-risk disease; MYCN amplification vs no MYCN amplification) [ Time Frame: Up to 4 years ]

Biospecimen Retention:   Samples With DNA
Blood, Bone Marrow


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Criteria

Inclusion Criteria:

  • Patient:

    • Diagnosis of neuroblastoma

      • Banked constitutional and genomic DNA within COG-ANBL00B1 Neuroblastoma Biology protocol or another COG Biology Protocol
      • At least 1.0 ?g of DNA available
  • Control (age, race, and gender-matched):

    • No diagnosis of cancer
    • May have other conditions, including any of the following:

      • Asthma
      • Inflammatory bowel disease
      • Attention-deficit disorder
      • Obesity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436696


Locations
Layout table for location information
United States, Mississippi
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, Pennsylvania
Childrens Oncology Group
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: John Maris Children's Oncology Group

Layout table for additonal information
Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT00436696     History of Changes
Other Study ID Numbers: ANBL06B1
NCI-2009-00403 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000522985
COG-ANBL06B1
ANBL06B1
ANBL06B1 ( Other Identifier: Childrens Oncology Group )
ANBL06B1 ( Other Identifier: CTEP )
First Posted: February 19, 2007    Key Record Dates
Last Update Posted: August 7, 2018
Last Verified: October 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroblastoma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue